Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

BACKGROUND: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. OBJECTIVE: The phase III GRIPHON trial...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cardiovasc Drugs
Autors principals: Coghlan, J. Gerry, Channick, Richard, Chin, Kelly, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Gaine, Sean
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2018
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5772136/
https://ncbi.nlm.nih.gov/pubmed/29307087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-017-0262-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars